Filtros de búsqueda

Lista de obras de Thomas Sandmann

Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes.

artículo científico publicado en 2015

BI-22CORRELATION OF MOLECULAR SUBTYPES WITH OVERALL SURVIVAL (OS) IN AVAGLIO, A RANDOMIZED, PLACEBO-CONTROLLED STUDY OF BEVACIZUMAB (BEV) PLUS RADIOTHERAPY (RT) AND TEMOZOLOMIDE (TMZ) FOR NEWLY DIAGNOSED GLIOBLASTOMA (GBM)

Brain delivery and activity of a lysosomal enzyme using a blood-brain barrier transport vehicle in mice

artículo científico publicado en 2020

High-Throughput and Sensitive Quantification of Circulating Tumor DNA by Microfluidic-Based Multiplex PCR and Next-Generation Sequencing.

artículo científico publicado en 2017

Obinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B-cell lymphoma: the phase II GATHER study

artículo científico publicado en 2018

Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial

artículo científico publicado en 2015

Radiologic progression of glioblastoma under therapy - an exploratory analysis of AVAglio

artículo científico publicado en 2017

Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O6-Methylguanine-DNA

artículo científico publicado en 2016

SUPT4H1 Depletion Leads to a Global Reduction in RNA

artículo científico publicado en 2019

Transcriptomic profiling of adjuvant colorectal cancer identifies three key prognostic biological processes and a disease specific role for granzyme B

artículo científico publicado en 2021

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda